|
|
700 Hansen Way
Palo Alto, CA 94304 USA
phone:(650) 845-7700
fax:650-845-7800
|
|
| Symbol |
TELK |
| Exchange |
NASDAQ |
| Founded |
1992 |
| Employees |
24 |
|
|
| www.telik.com/
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Small molecule drugs to treat cancer |
|
| Management |
| Michael M. Wick, M.D., Ph.D., Chairman, Chief Executive Officer and President; Steven R. Schow, Ph.D.,
Vice President, Research and Development; Gail L. Brown, M.D., Senior Vice President and Chief Medical Officer; Marc L. Steuer,
Senior Vice President, Business Development; Wendy K. Wee,
Principal Financial and Accounting Officer; William P. Kaplan, Esq.
Vice President, General Counsel and Corporate Secretary |
| |
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Telik Inc. discovers, develops, and commercializes novel, small-molecule drugs to treat cancer and other serious diseases. The Company uses its proprietary Target-Related Affinity Profiling (TRAP®) technology to measure the bonding between a small molecule and the Company’s proprietary reference panel of proteins, and in that manner creates a profile for each compound rather than test up to two million compounds in order to identify the few that interact selectively with a disease-related protein target, as is done in traditional small molecular screening, hence, TRAP® enables the rapid discovery and efficient optimization of small molecule drug candidates. Telik’s candidate TELINTRA® is a small molecule product designed to inhibit the enzyme glutathione S-transferase P1-1 (GSTP1-1), an overexpressed enzyme in many human cancer cells; TELINTRA® has been shown to increase white blood cell count in trials, and it is currently under clinical development for myelodyplastic syndrome and severe chronic idiopathic neutropenia. TELCYTA® is a cancer cell-activated chemotherapeutic that studies suggest is split into two active, cancer-fighting fragments upon contact with GSTP1-1, and has shown clinical activity against advanced ovarian, non-small cell lung, colon, and breast cancers. This earlier-stage biotechnology company also partners with select academic institutions and pharmaceutical and biotechnology companies to undertake new drug discovery programs. |
|
| Products / Services |
TELINTRA, TELCYTA,
|
|
| Technology / Differentiation |
| TRAP |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
